7 completed, 4 unknown, 2 not yet recruiting, 2 terminated. 10 Not applicable, 2 Phase 1, 1 Early Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 10 | Completed 4, Unknown 4, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Clinical High Risk for Psychosis: new trials by email Literature Review of Clinical High Risk for Psychosis trials Research Report on Clinical High Risk for Psychosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Stratification and Treatment in Early Psychosis Study - PROMOTE Cannabidiol (CBD), Placebo - Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis | Phase 3 | Not yet recruiting | University of Oxford | 586 | 2026-12-01 | 2026-10-08 |
| Eye-Movement Intervention for Cognitive Impairment Across Schizophrenia Spectrum Eye-Movement Training, Finger-Controlled Game Training - Schizophrenia, Cognitive Impairment | Not applicable | Not yet recruiting | Shanghai Mental Health Center | 160 | 2026-07-01 | 2026-07-14 |
| Metacognitive Training in Ultra-high Risk Metacognitive Training - Ultra-high Risk for Psychosis, Clinical High Risk for Psychosis | Not applicable | Unknown | Medical University of Vienna | 30 | 2023-10-21 | 2024-03-15 |
| Sacramento Clinical High Risk for Psychosis Stepped-Care Program Stepped-Care including Cognitive Behavioral Case Management - Clinical High Risk for Psychosis, Ultra High Risk for Psychosis | Not applicable | Recruiting | University of California, Davis | 223 | 2023-03-20 | 2025-12-15 |
| Endocannabinoid Activity Remodulation for Psychosis Liability in Youth Ultra-micronized Palmitoylethanolamide (PEA) - Clinical High Risk for Psychosis, Ultra High Risk for Psychosis | Not applicable | Unknown | University of Udine | 20 | 2022-11-01 | 2023-09-21 |
| Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST) InVEST - Clinical High Risk for Psychosis | Not applicable | Completed | Beth Israel Deaconess Medical Center | 26 | 2022-02-22 | 2026-01-23 |
| Feasibility of an Early Detection Program for Early Psychosis on a College Campus Psychosis, First Episode Psychosis | Completed | University of New Mexico | 25 | 2019-10-01 | 2024-04-01 | |
| The Predictive Role of Self-representation in Transition of Individuals at Clinical High Risk for Psychosis Virtual hand illusion (VHI) - Clinical High Risk for Psychosis | Completed | Shanghai Mental Health Center | 160 | 2019-07-06 | 2023-01-23 | |
| Glutamate Reducing Interventions in Schizophrenia Pomaglumetad methionil - Clinical High Risk for Psychosis | Phase 1 | Completed | New York State Psychiatric Institute | 16 | 2018-04-17 | 2021-12-01 |
| Evaluation of the Treatment Approach ROBIN Psychotherapy - Clinical High Risk for Psychosis | Not applicable | Unknown | University of Zurich | 30 | 2017-09-01 | 2019-02-04 |
| tDCS Coupled With Virtual Rehabilitation for Negative Symptoms in At-Risk Youth Active tDCS, Active VR Motivation Training, Sham tDCS - Clinical High Risk for Psychosis | Not applicable | Unknown | Centre for Addiction and Mental Health | 22 | 2016-10-01 | 2020-05-06 |
| Smartphone Applications Youth With Early Psychosis in Community Outpatient Settings Mobi mHealth app - Psychosis, Clinical High Risk for Psychosis | Not applicable | Completed | University of California, Davis | 60 | 2015-08-19 | 2017-09-18 |
| Gabapentin in Patients at Clinical Risk for Psychosis Gabapentin, Placebo - Clinical High Risk for Psychosis | Phase 1 / Phase 2 | Terminated | New York State Psychiatric Institute | 9 | 2015-08-01 | 2022-05-03 |
| Targeted Cognitive Training in Clinical High Risk (CHR) for Psychosis Targeted Cognitive Training, Computer Games - Clinical High Risk for Psychosis | Not applicable | Completed | Rush University Medical Center | 139 | 2015-03-01 | 2022-12-02 |
| Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis Aspirin, Placebo - Clinical High Risk for Psychosis | Early Phase 1 | Terminated | Yale University | 1 | 2015-01-01 | 2021-05-17 |
| Using Mobile Technology to Enhance Early Psychosis Treatment Delivery Mobile health application - Ginger.io - Psychosis, Clinical High Risk for Psychosis | Not applicable | Completed | University of California, Davis | 79 | 2014-12-14 | 2017-10-06 |
Psychotic Disorders (6) · Schizophrenia (3) · Cognitive Dysfunction (1)
Mental Disorders (8) · Schizophrenia Spectrum and Other Psychotic Disorders (8) · Cognition Disorders (1) · Neurocognitive Disorders (1)
Aspirin (1) · Cannabidiol (1) · Cognitive Behavioral Therapy (1) · Gabapentin (1) · LY 2140023 (1) · Psychotherapy (1) · poly(n-octyl methacrylate) (1) · pomaglumetad methionil (1)
University of California, Davis (3) · New York State Psychiatric Institute (2) · Shanghai Mental Health Center (2) · Beth Israel Deaconess Medical Center (1) · Centre for Addiction and Mental Health (1) · Medical University of Vienna (1) · Rush University Medical Center (1) · University of New Mexico (1) · University of Oxford (1) · University of Udine (1) · University of Zurich (1) · Yale University (1)
United States (9) · Austria (2) · Canada (2) · Italy (2) · Switzerland (2) · China (1) · Finland (1) · Germany (1) · Greece (1) · Netherlands (1) · Spain (1) · United Kingdom (1)
Annette Crisanti, PhD (1) · Christine I Hooker, PhD (1) · George Foussias, MD PhD FRCPC (1) · Jijun Wang, Doctoral (1) · Marco Colizzi, MD, PhD (1) · Michelle Friedman-Yakoobian, PHD (1) · Nilufar Mossaheb, MD (1) · Philip McGuire, PhD, MD (1) · Ragy Girgis, M.D. (1) · Scott Small, MD (1) · Scott W Woods, MD (1) · Tara A Niendam, Ph.D. (1) · Tianhong Zhang, Doctoral (1)
PMID 14656496, PMID 18411059, PMID 23273611, PMID 26719911, PMID 27374147, PMID 29036731, PMID 29804931, PMID 31244692, PMID 34309187, PMID 41316062, PMID 41378189
R01MH105246 (1), R34MH120777 (1), R61MH112800 (1)